Atossa Therapeutics, Inc. (ATOS)
After hours:
| Previous Close | 1.5000 |
| Open | 1.5200 |
| Bid | 1.5000 x 300 |
| Ask | 1.5300 x 100 |
| Day's Range | 1.4900 - 1.5300 |
| 52 Week Range | 0.6200 - 2.3100 |
| Volume | |
| Avg. Volume | 1,024,125 |
| Market Cap | 191.151M |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
FDA Update to Mammography Regulations in MQSA Final Rule is Effective TodaySEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its support of the U.S. Food and Drug Administration (FDA) for issuing a final rule to update the mammography regulations issued under the Mammography Quality Standards Act of 1992 (MQSA), which becomes effective today. Among the updates, the final rule requires mammography facilities to provid
- GlobeNewswire
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat and meet with investors. A recording of the fireside chat will be available here at 7:00
- GlobeNewswire
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,071,391) directed to compositions comprising endoxifen (in free base or salt forms) and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a cli
